Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.

KZR

Kezar Life Sciences (KZR)

Kezar Life Sciences Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:KZR
DateHeureSourceTitreSymboleSociété
03/12/202422h45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KZRKezar Life Sciences Inc
12/11/202422h18Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KZRKezar Life Sciences Inc
12/11/202422h01Business WireKezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:KZRKezar Life Sciences Inc
29/10/202422h05Edgar (US Regulatory)Form 8-A12B/A - Registration of securities [Section 12(b)]: [Amend]NASDAQ:KZRKezar Life Sciences Inc
28/10/202413h30Business WireKezar Life Sciences Announces 1-for-10 Reverse Stock SplitNASDAQ:KZRKezar Life Sciences Inc
17/10/202415h22Edgar (US Regulatory)Form 8-A12B - Registration of securities [Section 12(b)]NASDAQ:KZRKezar Life Sciences Inc
17/10/202414h35Business WireKezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights PlanNASDAQ:KZRKezar Life Sciences Inc
17/10/202414h30Business WireKezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE UpdateNASDAQ:KZRKezar Life Sciences Inc
10/10/202414h30Business WireKezar Confirms Receipt of Unsolicited, Non-Binding Acquisition ProposalNASDAQ:KZRKezar Life Sciences Inc
04/10/202423h00Business WireKezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus NephritisNASDAQ:KZRKezar Life Sciences Inc
30/09/202414h30Business WireKezar Life Sciences Announces Cessation of Enrollment and Dosing in the Phase 2b PALIZADE Trial of Zetomipzomib in Active Lupus Nephritis PatientsNASDAQ:KZRKezar Life Sciences Inc
04/09/202422h01Business WireKezar Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:KZRKezar Life Sciences Inc
13/08/202422h02Business WireKezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:KZRKezar Life Sciences Inc
26/07/202423h41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KZRKezar Life Sciences Inc
10/07/202422h01Business WireKezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:KZRKezar Life Sciences Inc
29/05/202422h01Business WireKezar Life Sciences to Participate in the Jefferies Global Healthcare ConferenceNASDAQ:KZRKezar Life Sciences Inc
09/05/202422h01Business WireKezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:KZRKezar Life Sciences Inc
06/05/202422h05Business WireKezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:KZRKezar Life Sciences Inc
14/03/202421h01Business WireKezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business UpdateNASDAQ:KZRKezar Life Sciences Inc
28/02/202422h01Business WireKezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care ConferenceNASDAQ:KZRKezar Life Sciences Inc
27/02/202400h30Business WireEverest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus NephritisNASDAQ:KZRKezar Life Sciences Inc
14/02/202412h50Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:KZRKezar Life Sciences Inc
17/01/202423h09Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:KZRKezar Life Sciences Inc
21/11/202322h01Business WireKezar Life Sciences to Present at the 6th Annual Evercore ISI HealthCONx ConferenceNASDAQ:KZRKezar Life Sciences Inc
13/11/202322h01Business WireKezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:KZRKezar Life Sciences Inc
03/10/202322h10Business WireKezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as Chief Executive OfficerNASDAQ:KZRKezar Life Sciences Inc
21/09/202302h30Dow Jones NewsStocks to Watch: FedEx, Kezar Life Sciences, TranscatNASDAQ:KZRKezar Life Sciences Inc
21/09/202300h30Business WireKezar Life Sciences and Everest Medicines Enter into an Agreement to Develop and Commercialize Zetomipzomib for Lupus Nephritis and other Potential Indications in Greater China, South Korea and Southeast AsiaNASDAQ:KZRKezar Life Sciences Inc
31/08/202322h01Business WireKezar Life Sciences to Participate in Three Upcoming Investor ConferencesNASDAQ:KZRKezar Life Sciences Inc
10/08/202322h01Business WireKezar Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:KZRKezar Life Sciences Inc
 Showing the most relevant articles for your search:NASDAQ:KZR

Dernières Valeurs Consultées

Delayed Upgrade Clock